812 related articles for article (PubMed ID: 20937945)
1. Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis.
Karussis D; Karageorgiou C; Vaknin-Dembinsky A; Gowda-Kurkalli B; Gomori JM; Kassis I; Bulte JW; Petrou P; Ben-Hur T; Abramsky O; Slavin S
Arch Neurol; 2010 Oct; 67(10):1187-94. PubMed ID: 20937945
[TBL] [Abstract][Full Text] [Related]
2. Phase I trial of repeated intrathecal autologous bone marrow-derived mesenchymal stromal cells in amyotrophic lateral sclerosis.
Oh KW; Moon C; Kim HY; Oh SI; Park J; Lee JH; Chang IY; Kim KS; Kim SH
Stem Cells Transl Med; 2015 Jun; 4(6):590-7. PubMed ID: 25934946
[TBL] [Abstract][Full Text] [Related]
3. A phase II clinical trial with repeated intrathecal injections of autologous mesenchymal stem cells in patients with amyotrophic lateral sclerosis.
Petrou P; Kassis I; Yaghmour NE; Ginzberg A; Karussis D
Front Biosci (Landmark Ed); 2021 Oct; 26(10):693-706. PubMed ID: 34719198
[No Abstract] [Full Text] [Related]
4. Phase I Trial of Intrathecal Mesenchymal Stem Cell-derived Neural Progenitors in Progressive Multiple Sclerosis.
Harris VK; Stark J; Vyshkina T; Blackshear L; Joo G; Stefanova V; Sara G; Sadiq SA
EBioMedicine; 2018 Mar; 29():23-30. PubMed ID: 29449193
[TBL] [Abstract][Full Text] [Related]
5. The immunomodulatory effects of human mesenchymal stem cells on peripheral blood mononuclear cells in ALS patients.
Kwon MS; Noh MY; Oh KW; Cho KA; Kang BY; Kim KS; Kim YS; Kim SH
J Neurochem; 2014 Oct; 131(2):206-18. PubMed ID: 24995608
[TBL] [Abstract][Full Text] [Related]
6. Immunomodulatory Properties of Bone Marrow Mesenchymal Stem Cells from Patients with Amyotrophic Lateral Sclerosis and Healthy Donors.
Javorkova E; Matejckova N; Zajicova A; Hermankova B; Hajkova M; Bohacova P; Kossl J; Krulova M; Holan V
J Neuroimmune Pharmacol; 2019 Jun; 14(2):215-225. PubMed ID: 30242613
[TBL] [Abstract][Full Text] [Related]
7. Safety and Clinical Effects of Mesenchymal Stem Cells Secreting Neurotrophic Factor Transplantation in Patients With Amyotrophic Lateral Sclerosis: Results of Phase 1/2 and 2a Clinical Trials.
Petrou P; Gothelf Y; Argov Z; Gotkine M; Levy YS; Kassis I; Vaknin-Dembinsky A; Ben-Hur T; Offen D; Abramsky O; Melamed E; Karussis D
JAMA Neurol; 2016 Mar; 73(3):337-44. PubMed ID: 26751635
[TBL] [Abstract][Full Text] [Related]
8. Mesenchymal stem cell transplantation in amyotrophic lateral sclerosis: A Phase I clinical trial.
Mazzini L; Ferrero I; Luparello V; Rustichelli D; Gunetti M; Mareschi K; Testa L; Stecco A; Tarletti R; Miglioretti M; Fava E; Nasuelli N; Cisari C; Massara M; Vercelli R; Oggioni GD; Carriero A; Cantello R; Monaco F; Fagioli F
Exp Neurol; 2010 May; 223(1):229-37. PubMed ID: 19682989
[TBL] [Abstract][Full Text] [Related]
9. Autologous bone marrow-derived stem cells in amyotrophic lateral sclerosis: a pilot study.
Prabhakar S; Marwaha N; Lal V; Sharma RR; Rajan R; Khandelwal N
Neurol India; 2012; 60(5):465-9. PubMed ID: 23135021
[TBL] [Abstract][Full Text] [Related]
10. Repeated Intrathecal Mesenchymal Stem Cells for Amyotrophic Lateral Sclerosis.
Oh KW; Noh MY; Kwon MS; Kim HY; Oh SI; Park J; Kim HJ; Ki CS; Kim SH
Ann Neurol; 2018 Sep; 84(3):361-373. PubMed ID: 30048006
[TBL] [Abstract][Full Text] [Related]
11. Beneficial effects of autologous mesenchymal stem cell transplantation in active progressive multiple sclerosis.
Petrou P; Kassis I; Levin N; Paul F; Backner Y; Benoliel T; Oertel FC; Scheel M; Hallimi M; Yaghmour N; Hur TB; Ginzberg A; Levy Y; Abramsky O; Karussis D
Brain; 2020 Dec; 143(12):3574-3588. PubMed ID: 33253391
[TBL] [Abstract][Full Text] [Related]
12. Transplantation of Mesenchymal Stromal Cells in Patients With Amyotrophic Lateral Sclerosis: Results of Phase I/IIa Clinical Trial.
Syková E; Rychmach P; Drahorádová I; Konrádová Š; Růžičková K; Voříšek I; Forostyak S; Homola A; Bojar M
Cell Transplant; 2017 Apr; 26(4):647-658. PubMed ID: 27938483
[TBL] [Abstract][Full Text] [Related]
13. Pilot trial of intravenous autologous culture-expanded mesenchymal stem cell transplantation in multiple sclerosis.
Cohen JA; Imrey PB; Planchon SM; Bermel RA; Fisher E; Fox RJ; Bar-Or A; Sharp SL; Skaramagas TT; Jagodnik P; Karafa M; Morrison S; Reese Koc J; Gerson SL; Lazarus HM
Mult Scler; 2018 Apr; 24(4):501-511. PubMed ID: 28381130
[TBL] [Abstract][Full Text] [Related]
14. Mesenchymal stem cells and conditioned media in the treatment of multiple sclerosis patients: Clinical, ophthalmological and radiological assessments of safety and efficacy.
Dahbour S; Jamali F; Alhattab D; Al-Radaideh A; Ababneh O; Al-Ryalat N; Al-Bdour M; Hourani B; Msallam M; Rasheed M; Huneiti A; Bahou Y; Tarawneh E; Awidi A
CNS Neurosci Ther; 2017 Nov; 23(11):866-874. PubMed ID: 28961381
[TBL] [Abstract][Full Text] [Related]
15. Safety of intrathecal autologous adipose-derived mesenchymal stromal cells in patients with ALS.
Staff NP; Madigan NN; Morris J; Jentoft M; Sorenson EJ; Butler G; Gastineau D; Dietz A; Windebank AJ
Neurology; 2016 Nov; 87(21):2230-2234. PubMed ID: 27784774
[TBL] [Abstract][Full Text] [Related]
16. Safety, tolerability, and activity of mesenchymal stem cells versus placebo in multiple sclerosis (MESEMS): a phase 2, randomised, double-blind crossover trial.
Uccelli A; Laroni A; Ali R; Battaglia MA; Blinkenberg M; Brundin L; Clanet M; Fernandez O; Marriot J; Muraro P; Nabavi SM; Oliveri RS; Radue E; Ramo Tello C; Schiavetti I; Sellner J; Sorensen PS; Sormani MP; Wuerfel JT; Freedman MS;
Lancet Neurol; 2021 Nov; 20(11):917-929. PubMed ID: 34687636
[TBL] [Abstract][Full Text] [Related]
17. Long-Term Clinical and Immunological Effects of Repeated Mesenchymal Stem Cell Injections in Patients With Progressive Forms of Multiple Sclerosis.
Petrou P; Kassis I; Ginzberg A; Halimi M; Yaghmour N; Abramsky O; Karussis D
Front Neurol; 2021; 12():639315. PubMed ID: 34135843
[No Abstract] [Full Text] [Related]
18. Umbilical Cord Mesenchymal Stem Cells in Amyotrophic Lateral Sclerosis: an Original Study.
Barczewska M; Maksymowicz S; Zdolińska-Malinowska I; Siwek T; Grudniak M
Stem Cell Rev Rep; 2020 Oct; 16(5):922-932. PubMed ID: 32725316
[TBL] [Abstract][Full Text] [Related]
19. Biological markers of mesenchymal stromal cells as predictors of response to autologous stem cell transplantation in patients with amyotrophic lateral sclerosis: an investigator-initiated trial and in vivo study.
Kim HY; Kim H; Oh KW; Oh SI; Koh SH; Baik W; Noh MY; Kim KS; Kim SH
Stem Cells; 2014 Oct; 32(10):2724-31. PubMed ID: 24966156
[TBL] [Abstract][Full Text] [Related]
20. Mesenchymal stromal cell transplantation in amyotrophic lateral sclerosis: a long-term safety study.
Mazzini L; Mareschi K; Ferrero I; Miglioretti M; Stecco A; Servo S; Carriero A; Monaco F; Fagioli F
Cytotherapy; 2012 Jan; 14(1):56-60. PubMed ID: 21954839
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
